Overview Financials News + Filings Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Quarterly results
|
Nabriva Therapeutics plc (NBRV)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
08/14/2023 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
07/31/2023 |
8-K
| Quarterly results |
07/24/2023 |
8-K
| Quarterly results |
07/10/2023 |
3
| HOGAN H MICHAEL III (CEO) has filed a Form 3 on Nabriva Therapeutics plc |
07/10/2023 |
3
| Maggio David (CFO) has filed a Form 3 on Nabriva Therapeutics plc |
07/07/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
06/01/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
05/15/2023 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
04/17/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
03/31/2023 |
NT 10-K
| Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405: |
01/31/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
01/31/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
01/20/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
01/10/2023 |
4
| Gelone Steven P. (President and COO) has filed a Form 4 on Nabriva Therapeutics plc
Txns:
| Paid exercise price by delivering 5 shares
@ $1.3, valued at
$6.5 |
|
01/10/2023 |
4
| Schroeder Theodore R (CEO) has filed a Form 4 on Nabriva Therapeutics plc
Txns:
| Paid exercise price by delivering 11 shares
@ $1.3, valued at
$14.3 |
|
01/09/2023 |
8-K
| Termination of a Material Definitive Agreement, Cost Associated with Exit or Disposal Activities, Other Events, Financial Sta... |
01/04/2023 |
4
| Schroeder Theodore R (CEO) has filed a Form 4 on Nabriva Therapeutics plc
Txns:
| Paid exercise price by delivering 5 shares
@ $1.89, valued at
$9.5 |
|
01/04/2023 |
4
| Gelone Steven P. (President and COO) has filed a Form 4 on Nabriva Therapeutics plc
Txns:
| Paid exercise price by delivering 3 shares
@ $1.89, valued at
$5.7 |
|
12/08/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
12/08/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
12/02/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
12/02/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
11/28/2022 |
8-K
| Quarterly results |
11/10/2022 |
8-K
| Quarterly results |
11/10/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
11/08/2022 |
4
| Gelone Steven P. (President and COO) has filed a Form 4 on Nabriva Therapeutics plc
Txns:
| Paid exercise price by delivering 4 shares
@ $2.2392, valued at
$9 |
|
11/08/2022 |
4
| Schroeder Theodore R (CEO) has filed a Form 4 on Nabriva Therapeutics plc
Txns:
| Paid exercise price by delivering 10 shares
@ $2.2392, valued at
$22.4 |
|
11/01/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
11/01/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
10/11/2022 |
4
| Schroeder Theodore R (CEO) has filed a Form 4 on Nabriva Therapeutics plc
Txns:
| Paid exercise price by delivering 9 shares
@ $2.72, valued at
$24.5 |
|
10/11/2022 |
4
| Gelone Steven P. (President and COO) has filed a Form 4 on Nabriva Therapeutics plc
Txns:
| Paid exercise price by delivering 4 shares
@ $2.72, valued at
$10.9 |
|
10/04/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
10/04/2022 |
4
| Schroeder Theodore R (CEO) has filed a Form 4 on Nabriva Therapeutics plc
Txns:
| Paid exercise price by delivering 5 shares
@ $2.08, valued at
$10.4 |
|
10/04/2022 |
8-K
| Other Events Interactive Data |
|
|
|